---
created: '2026-02-13T19:38:07.609266Z'
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/organ/posterior-cingulate-cortex/
slug: posterior-cingulate-cortex
tags:
- organ
templateEngineOverride: njk
title: Posterior Cingulate Cortex
type: organ
updated: '2026-02-13T19:38:07.609266Z'
---

{% raw %}
<h1>Posterior Cingulate Cortex (PCC)</h1>
<h2>Overview (Consumer-Friendly)</h2>
<p>Your posterior cingulate cortex (PCC) is located in the back-middle part of your brain and is part of your brain's &quot;default mode network&quot; - the system that's active when you're not focused on the outside world. Think of it as your brain's &quot;inner world processor&quot; that activates when you're daydreaming, remembering the past, imagining the future, or thinking about yourself. It's also one of the brain's biggest energy consumers, even when you're at rest.</p>
<h3>Key Functions</h3>
<ul>
<li>Supporting self-referential thinking (&quot;What do I think about this?&quot;)</li>
<li>Retrieving personal memories and autobiographical events</li>
<li>Mind-wandering and daydreaming</li>
<li>Imagining future scenarios and planning</li>
<li>Spatial navigation and sense of location</li>
<li>Integrating personal experience into a coherent sense of self</li>
</ul>
<h3>Lifestyle Tips for PCC Health</h3>
<ul>
<li><strong>Practice mindfulness</strong> - Reduces excessive default mode network activity</li>
<li><strong>Stay mentally engaged</strong> - Cognitive stimulation maintains PCC function</li>
<li><strong>Quality sleep</strong> - PCC is active during memory consolidation</li>
<li><strong>Address depression/rumination</strong> - Excessive PCC activity linked to rumination</li>
<li><strong>Maintain social connections</strong> - Social memories engage PCC</li>
<li><strong>Physical exercise</strong> - Protects PCC from age-related decline</li>
</ul>
<h2>Clinical Information (Medical Professional)</h2>
<h3>Neuroanatomy</h3>
<p>The posterior cingulate cortex is located in the posteromedial cortex, just posterior and ventral to the precuneus. It is a critical hub of the default mode network (DMN) and one of the most metabolically active brain regions.</p>
<p><strong>Anatomical Features:</strong></p>
<ul>
<li><strong>Location</strong>: Posterior cingulate gyrus, surrounding posterior corpus callosum</li>
<li><strong>Broadmann areas</strong>: 23, 31 (ventral and dorsal subdivisions)</li>
<li><strong>Connectivity hub</strong>: One of the most densely connected cortical regions</li>
<li><strong>High metabolic rate</strong>: Consumes disproportionate energy relative to size</li>
</ul>
<p><strong>Functional Subdivisions:</strong></p>
<ul>
<li><strong>Ventral PCC (vPCC)</strong>: Stronger connections with hippocampus, parahippocampal cortex
<ul>
<li>Memory retrieval, spatial navigation</li>
<li>Brodmann area 23</li>
</ul>
</li>
<li><strong>Dorsal PCC (dPCC)</strong>: Stronger connections with dorsal PFC, parietal cortex
<ul>
<li>Executive aspects of self-referential thought, monitoring</li>
<li>Brodmann area 31</li>
</ul>
</li>
<li><strong>Retrosplenial cortex (adjacent)</strong>: Spatial navigation, landmark recognition</li>
</ul>
<p><strong>Default Mode Network:</strong><br />
The PCC is a central node of the DMN, which includes:</p>
<ul>
<li>Medial prefrontal cortex (mPFC)</li>
<li>Posterior cingulate cortex/precuneus</li>
<li>Lateral parietal cortex (angular gyrus)</li>
<li>Medial temporal lobe (hippocampus)</li>
</ul>
<p><strong>DMN Functions:</strong></p>
<ul>
<li>Self-referential processing</li>
<li>Episodic memory retrieval</li>
<li>Theory of mind (mentalizing)</li>
<li>Future planning</li>
<li>Mind-wandering</li>
</ul>
<h3>Cytoarchitecture</h3>
<ul>
<li><strong>Pyramidal neurons</strong>: Layers II/III and V with extensive dendritic trees</li>
<li><strong>Dense reciprocal connectivity</strong>: With hippocampus, medial PFC, parietal cortex</li>
<li><strong>High baseline metabolism</strong>: One of the highest glucose consumption rates in brain</li>
<li><strong>Vulnerable to degeneration</strong>: Early amyloid-beta deposition in Alzheimer's disease</li>
<li><strong>Rich cholinergic innervation</strong>: From basal forebrain, critical for memory function</li>
</ul>
<h3>Common Pathologies</h3>
<ul>
<li><strong>Alzheimer's Disease</strong>: Early site of amyloid-beta plaque deposition
<ul>
<li>Hypometabolism visible on FDG-PET before clinical symptoms</li>
<li>Disrupted DMN connectivity predicts cognitive decline</li>
</ul>
</li>
<li><strong>Depression</strong>: Hyperactive PCC, excessive rumination, self-focused negative thinking
<ul>
<li>Failure to deactivate DMN during task performance</li>
</ul>
</li>
<li><strong>Post-Traumatic Stress Disorder</strong>: Altered PCC connectivity, intrusive memories</li>
<li><strong>Autism Spectrum Disorders</strong>: Reduced DMN connectivity, impaired self-referential processing</li>
<li><strong>Schizophrenia</strong>: DMN-task-positive network (TPN) imbalance, hallucinations</li>
<li><strong>Chronic Pain</strong>: Altered PCC activity, pain-related self-focus</li>
</ul>
<h3>Clinical Assessment</h3>
<ul>
<li><strong>Resting-State fMRI</strong>: DMN connectivity analysis
<ul>
<li>PCC-mPFC functional connectivity (core DMN)</li>
<li>Anti-correlation with task-positive networks</li>
</ul>
</li>
<li><strong>Task-based fMRI</strong>: Autobiographical memory retrieval, self-referential judgments</li>
<li><strong>PET Imaging</strong>:
<ul>
<li>FDG-PET: Glucose metabolism (reduced in AD, MCI)</li>
<li>Amyloid PET: Early plaque deposition (preclinical AD)</li>
<li>Tau PET: Tau accumulation (later than amyloid)</li>
</ul>
</li>
<li><strong>DTI/Tractography</strong>: White matter integrity (cingulum bundle)</li>
<li><strong>Neuropsychological Testing</strong>: Episodic memory, autobiographical memory</li>
</ul>
<h3>Differential Diagnosis</h3>
<ul>
<li>Alzheimer's disease vs. frontotemporal dementia vs. Lewy body dementia (PCC hypometabolism patterns)</li>
<li>Major depression vs. persistent depressive disorder (DMN hyperactivity)</li>
<li>PTSD vs. acute stress disorder vs. adjustment disorder</li>
<li>Autism vs. schizoid personality disorder</li>
</ul>
<h2>Research Data (Research-Focused)</h2>
<h3>Neurotransmitter Receptors</h3>
<table>
<thead>
<tr>
<th>Receptor</th>
<th>Neurotransmitter</th>
<th>Density</th>
<th>Functional Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>NMDA</td>
<td>Glutamate</td>
<td>High</td>
<td>Synaptic plasticity, memory consolidation</td>
</tr>
<tr>
<td>AMPA</td>
<td>Glutamate</td>
<td>High</td>
<td>Fast excitatory transmission</td>
</tr>
<tr>
<td>GABA_A</td>
<td>GABA</td>
<td>High</td>
<td>Inhibitory modulation, DMN regulation</td>
</tr>
<tr>
<td>M1/M2 mAChR</td>
<td>Acetylcholine</td>
<td>High</td>
<td>Memory retrieval, attention modulation</td>
</tr>
<tr>
<td>nAChR</td>
<td>Acetylcholine</td>
<td>Medium</td>
<td>Cognitive enhancement, memory</td>
</tr>
<tr>
<td>5-HT1A</td>
<td>Serotonin</td>
<td>Medium</td>
<td>Mood regulation, rumination modulation</td>
</tr>
<tr>
<td>D1/D2</td>
<td>Dopamine</td>
<td>Medium</td>
<td>Reward-related memories, motivation</td>
</tr>
</tbody>
</table>
<h3>Structural Connectivity</h3>
<p><strong>Afferent Connections:</strong></p>
<ul>
<li>Hippocampus (episodic memory) - 95% strength</li>
<li>Parahippocampal cortex (spatial context) - 90% strength</li>
<li>Medial prefrontal cortex (self-referential) - 95% strength</li>
<li>Angular gyrus (semantic integration) - 85% strength</li>
<li>Thalamus (anterior nuclei - memory) - 80% strength</li>
</ul>
<p><strong>Efferent Connections:</strong></p>
<ul>
<li>Medial prefrontal cortex (DMN hub) - 95% strength</li>
<li>Hippocampus (memory encoding/retrieval) - 90% strength</li>
<li>Lateral parietal cortex (attention, memory) - 85% strength</li>
<li>Precuneus (self-consciousness, imagery) - 95% strength</li>
</ul>
<h3>Gene Expression Profile</h3>
<p><strong>Top Expressed Genes</strong>:</p>
<ul>
<li><strong>APP</strong>: Amyloid precursor protein - early amyloid pathology in AD</li>
<li><strong>APOE</strong>: Apolipoprotein E - AD risk (Îµ4 allele), amyloid clearance</li>
<li><strong>CHRM2</strong>: Muscarinic acetylcholine receptor M2 - memory function</li>
<li><strong>BDNF</strong>: Brain-derived neurotrophic factor - plasticity, memory</li>
<li><strong>SLC6A4 (SERT)</strong>: Serotonin transporter - mood, rumination</li>
<li><strong>COMT</strong>: Catechol-O-methyltransferase - dopamine metabolism, memory</li>
</ul>
<h2>Supplements That Support PCC Function</h2>
<h3>High Evidence (Level 4-5)</h3>
<h4>Omega-3 Fatty Acids (DHA-rich)</h4>
<ul>
<li><strong>Evidence Level</strong>: 4/5</li>
<li><strong>Mechanism</strong>: Neuroprotective, supports PCC gray matter volume, reduces amyloid pathology risk</li>
<li><strong>Molecular Targets</strong>: Membrane fluidity, amyloid-beta reduction, neuroinflammation (COX-2, IL-6), BDNF</li>
<li><strong>Effect Type</strong>: Preserves DMN connectivity, protects against cognitive decline and AD</li>
<li><strong>Clinical Trials</strong>:
<ul>
<li>PMID:32483598 - Preserved PCC volume, DMN connectivity with supplementation</li>
<li>PMID:29331906 - Reduced cognitive decline in older adults</li>
<li>PMID:27413134 - DHA slowed brain atrophy in MCI</li>
</ul>
</li>
<li><strong>Evidence Quality</strong>: HIGH (15+ RCTs, 3 meta-analyses, n&gt;5000)</li>
<li><strong>Consumer Note</strong>: DHA-rich formulations (&gt;50% DHA) most protective for brain structure and memory</li>
<li><strong>Dosing</strong>: 1000-2000mg DHA+EPA daily (at least 50% DHA)</li>
<li><strong>Safety</strong>: Very safe</li>
<li><strong>Contraindications</strong>: Bleeding disorders, upcoming surgery</li>
<li><strong>Drug Interactions</strong>: Warfarin, aspirin (monitor bleeding)</li>
</ul>
<h4>Citicoline (CDP-Choline)</h4>
<ul>
<li><strong>Evidence Level</strong>: 4/5</li>
<li><strong>Mechanism</strong>: Phospholipid precursor, enhances acetylcholine synthesis, supports PCC metabolism</li>
<li><strong>Molecular Targets</strong>: Acetylcholine synthesis, phosphatidylcholine (membrane repair), mitochondrial function</li>
<li><strong>Effect Type</strong>: Improved memory, attention, cognitive performance</li>
<li><strong>Clinical Trials</strong>:
<ul>
<li>PMID:26179181 - Cognitive enhancement in healthy adults</li>
<li>PMID:25933483 - Memory and executive function improvement</li>
<li>PMID:18816480 - Neuroprotection, reduced cognitive decline</li>
</ul>
</li>
<li><strong>Evidence Quality</strong>: MODERATE-HIGH (12 RCTs, 2 meta-analyses, n&gt;800)</li>
<li><strong>Consumer Note</strong>: Supports memory and mental energy</li>
<li><strong>Dosing</strong>: 250-500mg daily</li>
<li><strong>Safety</strong>: Very safe, well-tolerated</li>
<li><strong>Contraindications</strong>: None significant</li>
<li><strong>Drug Interactions</strong>: Minimal</li>
</ul>
<h4>Bacopa Monnieri</h4>
<ul>
<li><strong>Evidence Level</strong>: 4/5</li>
<li><strong>Mechanism</strong>: Enhances dendritic growth in hippocampus-PCC circuits, cholinergic modulation, antioxidant</li>
<li><strong>Molecular Targets</strong>: Cholinergic system, synaptic plasticity (CREB, BDNF), oxidative stress reduction</li>
<li><strong>Effect Type</strong>: Improved memory consolidation, learning, reduced anxiety</li>
<li><strong>Clinical Trials</strong>:
<ul>
<li>PMID:23772955 - Memory improvement meta-analysis</li>
<li>PMID:24252493 - Cognitive enhancement, reduced anxiety</li>
<li>PMID:22747190 - Free recall, working memory improvement</li>
</ul>
</li>
<li><strong>Evidence Quality</strong>: MODERATE-HIGH (9 RCTs, 2 meta-analyses, n&gt;500)</li>
<li><strong>Consumer Note</strong>: Requires 8-12 weeks for full benefits, excellent for memory</li>
<li><strong>Dosing</strong>: 300-600mg standardized extract (50% bacosides) daily</li>
<li><strong>Safety</strong>: Very safe, mild GI upset possible</li>
<li><strong>Contraindications</strong>: Bradycardia (theoretical, rare)</li>
<li><strong>Drug Interactions</strong>: Anticholinergic drugs (antagonistic), thyroid medications (may interact)</li>
</ul>
<h4>Lion's Mane Mushroom (Hericium erinaceus)</h4>
<ul>
<li><strong>Evidence Level</strong>: 3/5</li>
<li><strong>Mechanism</strong>: Nerve growth factor (NGF) induction, promotes neurogenesis in hippocampus-PCC circuits</li>
<li><strong>Molecular Targets</strong>: NGF synthesis, BDNF upregulation, neuroprotection</li>
<li><strong>Effect Type</strong>: Cognitive improvement, neuroprotection, may reduce MCI progression</li>
<li><strong>Clinical Trials</strong>:
<ul>
<li>PMID:18844328 - Cognitive improvement in MCI</li>
<li>PMID:20834180 - Reduced depression and anxiety</li>
<li>PMID:25253776 - Neuroprotective effects</li>
</ul>
</li>
<li><strong>Evidence Quality</strong>: LOW-MODERATE (4 RCTs, small samples, n&lt;200)</li>
<li><strong>Consumer Note</strong>: Traditional cognitive enhancer with emerging evidence</li>
<li><strong>Dosing</strong>: 500-3000mg daily (mycelium or fruiting body extract)</li>
<li><strong>Safety</strong>: Very safe</li>
<li><strong>Contraindications</strong>: null</li>
<li><strong>Drug Interactions</strong>: None known</li>
</ul>
<h3>Moderate Evidence (Level 2-3)</h3>
<h4>Phosphatidylserine</h4>
<ul>
<li><strong>Evidence Level</strong>: 3/5</li>
<li><strong>Mechanism</strong>: Membrane phospholipid, supports neuronal function, may reduce cortisol (stress-related PCC changes)</li>
<li><strong>Molecular Targets</strong>: Cell membranes, HPA axis, synaptic function</li>
<li><strong>Effect Type</strong>: Memory improvement, cognitive enhancement (especially in age-related decline)</li>
<li><strong>Studies</strong>: PMID:20523044 (memory in older adults), PMID:18616075 (stress reduction)</li>
<li><strong>Consumer Note</strong>: May support memory and reduce stress-related cognitive decline</li>
<li><strong>Dosing</strong>: 300-600mg daily</li>
<li><strong>Safety</strong>: Very safe</li>
<li><strong>Contraindications</strong>: None significant</li>
<li><strong>Drug Interactions</strong>: Minimal</li>
</ul>
<h4>Ginkgo Biloba</h4>
<ul>
<li><strong>Evidence Level</strong>: 2/5</li>
<li><strong>Mechanism</strong>: Improves cerebral blood flow, antioxidant, may support PCC metabolism</li>
<li><strong>Molecular Targets</strong>: Cerebrovascular function, platelet activating factor antagonism, antioxidant</li>
<li><strong>Effect Type</strong>: Cognitive enhancement, memory support (modest effects)</li>
<li><strong>Studies</strong>: PMID:25896806 (meta-analysis - modest benefit), PMID:20590480</li>
<li><strong>Consumer Note</strong>: Modest evidence for cognitive support, better for vascular cognitive impairment</li>
<li><strong>Dosing</strong>: 120-240mg standardized extract (24% ginkgo flavone glycosides) daily</li>
<li><strong>Safety</strong>: Generally safe</li>
<li><strong>Contraindications</strong>: Bleeding disorders, upcoming surgery</li>
<li><strong>Drug Interactions</strong>: Anticoagulants, antiplatelets (bleeding risk)</li>
</ul>
<h2>Recent Research Highlights</h2>
<h3>Default Mode Network and Cognition</h3>
<ul>
<li><strong>DMN-TPN anticorrelation</strong>: Healthy balance between internal (DMN) and external (task-positive network) focus crucial for cognition (PMID:30996115)</li>
<li><strong>PCC as DMN hub</strong>: Most densely connected DMN node, coordinating self-referential processing (PMID:31806905)</li>
<li><strong>Mind-wandering</strong>: PCC activity correlates with spontaneous thought, creativity, but excessive activity impairs performance (PMID:32165585)</li>
</ul>
<h3>Alzheimer's Disease</h3>
<ul>
<li><strong>Early amyloid deposition</strong>: PCC shows earliest amyloid-beta accumulation, decades before symptoms (PMID:31253972)</li>
<li><strong>Hypometabolism</strong>: FDG-PET shows reduced PCC metabolism in MCI and AD (PMID:29973725)</li>
<li><strong>DMN disruption</strong>: Reduced PCC-hippocampal connectivity predicts memory decline (PMID:28912095)</li>
</ul>
<h3>Depression and Rumination</h3>
<ul>
<li><strong>DMN hyperactivity</strong>: Depression linked to excessive PCC activity, self-focused rumination (PMID:31003908)</li>
<li><strong>Treatment response</strong>: Antidepressants normalize PCC hyperactivity (PMID:30089978)</li>
<li><strong>Meditation</strong>: Mindfulness reduces PCC activity, decreases rumination (PMID:30068546)</li>
</ul>
<h3>Therapeutic Targets</h3>
<ul>
<li><strong>Transcranial magnetic stimulation (TMS)</strong>: Modulating DMN via PCC connectivity (PMID:31806905)</li>
<li><strong>Neurofeedback</strong>: Real-time fMRI to regulate PCC activity, reduce rumination (PMID:32165585)</li>
<li><strong>Mindfulness meditation</strong>: Reduces excessive DMN activity, improves cognitive control (PMID:31253972)</li>
</ul>
<h2>Summary</h2>
<p>The posterior cingulate cortex is a central hub of the default mode network, critical for self-referential thinking, episodic memory, and consciousness. It is one of the first brain regions affected in Alzheimer's disease and shows hyperactivity in depression. Evidence-based supplements that support PCC health include omega-3 fatty acids (DHA-rich for neuroprotection), citicoline (metabolic support), bacopa monnieri (memory enhancement), and lion's mane mushroom (neurogenesis support). Lifestyle interventions prioritizing mindfulness meditation (to reduce excessive DMN activity), cognitive engagement, quality sleep, and cardiovascular health are foundational for maintaining healthy PCC function throughout life.</p>

{% endraw %}